Skip navigation

Low-dose aspirin use and cognitive function in older age: A systematic review and meta-analysis

Low-dose aspirin use and cognitive function in older age: A systematic review and meta-analysis

Veronese, Nicola, Stubbs, Brendon, Maggi, Stefania, Thompson, Trevor ORCID: 0000-0001-9880-782X, Schofield, Patricia, Muller, Christoph, Tseng, Ping-Tao, Lin, Pao-Yen, Carvalho, André F. and Solmi, Marco (2017) Low-dose aspirin use and cognitive function in older age: A systematic review and meta-analysis. Journal of the American Geriatric Society, 65 (8). pp. 1763-1768. ISSN 0002-8614 (Print), 1532-5415 (Online) (doi:https://doi.org/10.1111/jgs.14883)

[img]
Preview
PDF (Author Accepted Manuscript)
16755 THOMPSON_Low-dose_Aspirin_Use_&_Cognitive_Function_2017.pdf - Accepted Version

Download (454kB) | Preview

Abstract

OBJECTIVES:
To investigate whether low-dose aspirin (<300 mg/d) can influence the onset of cognitive impair- ment or dementia in observational studies and improve cognitive test scores in randomized controlled trials (RCTs) in participants without dementia.

DESIGN:
Systematic review and meta-analysis. SETTING: Observational and interventional studies.

PARTICIPANTS:
Individuals with no dementia or cognitive impairment initially.

MEASUREMENTS:
Odds ratios (ORs) and 95% confi- dence intervals (CIs), adjusted for the maximum number of covariates from each study, were used to summarize data on the incidence of dementia and cognitive impair- ment in observational studies. Standardized mean differ- ences (SMDs) were used for cognitive test scores in RCTs. RESULTS: Of 2,341 potentially eligible articles, eight studies were included and provided data for 36,196 partic- ipants without dementia or cognitive impairment at base- line (mean age 66, 63% female). After adjusting for a median of three potential confounders over a median fol- low-up period of 6 years, chronic use of low-dose aspirin was not associated with onset of dementia or cognitive impairment (5 studies, N = 26,159; OR = 0.82, 95% CI = 0.55–1.22, P = .33, I2 = 67%). In three RCTs (N = 10,037; median follow-up 5 years), the use of low- dose aspirin was not associated with significantly better global cognition (SMD=0.005, 95% CI=–0.04–0.05, P = .84, I2 = 0%) in individuals without dementia. Adher- ence was lower in participants taking aspirin than in con- trols, and the incidence of adverse events was higher.

CONCLUSION:
This review found no evidence that low- dose aspirin buffers against cognitive decline or dementia or improves cognitive test scores in RCTs. J Am Geriatr Soc 2017.

Item Type: Article
Uncontrolled Keywords: Aspirin; Dementia; Cognitive impairment; Meta-analysis
Faculty / School / Research Centre / Research Group: Faculty of Education, Health & Human Sciences
Faculty of Education, Health & Human Sciences > School of Human Sciences (HUM)
Last Modified: 29 Apr 2018 21:28
URI: http://gala.gre.ac.uk/id/eprint/16755

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics